Table 4. Adverse events recorded in the study (n=60 completed patients).
| Adverse eventa | DTFC, n (%) | BTFC, n (%) | P-value |
|---|---|---|---|
| Bitter taste | 11 (18.3) | 0 (0) | 0.001 |
| Stinging | 10 (16.7) | 1 (1.7) | 0.012 |
| Conjunctival hyperaemia | 3 (5.0) | 10 (16.7) | 0.039 |
| Itchiness | 1 (1.7) | 7 (11.7) | 0.070 |
| Burning | 4 (6.7) | 0 (0) | 0.125 |
| Systemic hypotension | 0 (0) | 4 (6.7) | 0.125 |
| Dry mouth | 0 (0) | 4 (6.7) | 0.125 |
| Foreign body sensation | 0 (0) | 3 (5.0) | 0.250 |
| Dry eye sensation | 1 (1.7) | 3 (5.0) | 0.625 |
| Fatigue | 1 (1.7) | 3 (5.0) | 0.625 |
| Watering | 1 (1.7) | 2 (3.3) | 1.000 |
| SPK | 1 (1.7) | 0 (0) | 1.000 |
| Ocular discharge | 0 (0) | 1 (1.7) | 1.000 |
| Eyelid swelling | 1 (1.7) | 0 (0) | 1.000 |
| Headache | 0 (0) | 1 (1.7) | 1.000 |
| Dizziness | 0 (0) | 1 (1.7) | 1.000 |
| Drowsiness | 0 (0) | 1 (1.7) | 1.000 |
Abbreviations: BTFC, brimonidine/timolol-fixed combination; CI, confidence interval; DTFC: dorzolamide/timolol-fixed combination.
a
Some patients experienced multiple adverse events.